Ann: FY23 Annual Report, page-6

Also worth noting the simple but positive reference to Labcon.

"We are also seeing opportunities with end customers through Labcon."

Looking at the on screen ( I appreciate that isn't the full picture) sell side this could move very quickly with the Fuji news expected soon. Would be great to see some consolidation and launch from a higher base. Exciting to think about BCT finally being valued for potential and seeing some further big pharma names on board.